Bruce A. Kottke
Mayo Clinic
117 Papers
1.7K Citations
Bruce A. Kottke is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Cholesterol & Apolipoprotein B. The author has an hindex of 34, co-authored 117 publications. Previous affiliations of Bruce A. Kottke include University College London & University of Minnesota.
Chat about Author
Papers
Apolipoproteins and Coronary Artery Disease
Bruce A. Kottke,Alan R. Zinsmeister,David R. Holmes,Robert Kneller,Brenda J. Hallaway,Simon J.T. Mao +5 more
- 01 May 1986
TL;DR: Plasma apolipoprotein levels (especially A-I and A-II) may be considerably better markers for coronary artery disease than traditional lipid determinations.
170
Analysis of plasma lipids and apolipoproteins in insulin-dependent and noninsulin-dependent diabetics
Esperanza R. Briones,Esperanza R. Briones,Simon J.T. Mao,Simon J.T. Mao,Pasquale Palumbo,Pasquale Palumbo,William M. O'Fallon,William M. O'Fallon,W. Chenoweth,W. Chenoweth,Bruce A. Kottke,Bruce A. Kottke +11 more
TL;DR: In the IDDM subjects, but not in the NIDDM subjects the incidence of CAD and/or PAD was associated with the decreased apo A-I levels as evaluated by a univariate analysis.
129
Association of risk factor variables and coronary artery disease documented with angiography.
TL;DR: Despite highly significant associations between risk factors and the presence of coronary artery disease, the discrimination did not provide sufficient separation of the groups to give results that are useful diagnostically in individual patients.
116
•Journal Article
The gender-specific apolipoprotein E genotype influence on the distribution of lipids and apolipoproteins in the population of Rochester, MN. I. Pleiotropic effects on means and variances.
TL;DR: How heterogeneity of risk-factor-trait variance among genotype/gender-specific subgroups of the population at large may influence the evaluation of risk of coronary artery disease is demonstrated.
115
Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.
Jeff A. Etchason,Todd D. Miller,Ray W. Squires,Thomas G. Allison,Gerald T. Gau,James K. Marttila,Bruce A. Kottke +6 more
- 01 Jan 1991
TL;DR: Hepatitis developed in five patients who were taking low dosages (3 g/day or less) of time-release niacin and this manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacIn.
101